Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02267044
Other study ID # 14061
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2014
Est. completion date April 2017

Study information

Verified date October 2018
Source TriHealth Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Shoulder replacement surgery is recognized as having the potential to cause a considerable amount of postoperative pain. Adequate management of pain after surgery is necessary not only to improve the patient's wellbeing but also to facilitate recovery. Several regional anesthesia techniques are available to combat postoperative pain in the shoulder replacement surgery patient, however, which method provides superior pain relief remains unknown. The purpose of this study is to examine the effectiveness of a continuous interscalene block versus a single shot interscalene block for postoperative pain relief in the shoulder replacement patient.

Patients undergoing shoulder replacement surgery will experience more effective pain relief with a continuous interscalene block versus and single shot interscalene block.


Description:

This is a prospective randomized controlled trial. 76 patients receiving either primary total shoulder replacement, hemiarthroplasty, or reverse total shoulder replacement will be randomized to a regional anesthesia technique as part of their surgical procedure. 38 patients will receive a single shot interscalene block containing ropivicaine and 38 patients will receive a continuous interscalene block containing ropivicaine.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date April 2017
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Surgical candidate for primary total shoulder replacement, hemiarthroplasty, or reverse total shoulder replacement

- patient must be 18 years or older and willing to sign and date an Institutional Review Board informed consent form, and

- must be able to understand and agree to follow study protocol.

Exclusion Criteria:

- severe bronchopulmonary disease,

- oxygen dependent,

- existing nerve injury,

- BMI > 40,

- coagulation disorders,

- allergy to ropivicaine,

- history of drug or alcohol abuse,

- American Academy of Anaesthesiologists physical status classification > lll,

- pregnant women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ropivacaine
The drug used for the interscalene blocks

Locations

Country Name City State
United States Good Samaritan Hospital Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
TriHealth Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Borgeat A, Tewes E, Biasca N, Gerber C. Patient-controlled interscalene analgesia with ropivacaine after major shoulder surgery: PCIA vs PCA. Br J Anaesth. 1998 Oct;81(4):603-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Score Measure Patients will be assessed for pain levels by visual analog scale while in the hospital per nursing protocol. Electronic Medical Record will be used to acquire pain scores. participants will be followed for the duration of the hospital stay, an expected average of 3 days
Secondary Morphine Sulfate Equivalence consumption Total Morphine Sulfate equivalence consumption for each post-operative day while in the hospital will be collected through Electronic medical record. participants morphine sulfate consumption will be gathered for the duration of the hospital stay, an expected average of 3 days
Secondary Pain control Satisfaction Score Patient's post operative pain control satisfaction score will be obtained at the first post operative follow up visit with the physician which is expected to occur on avearage 10 days after surgery 10 day post operative